Cloud-clone
SKU(재고 관리 코드):LMA145Ra
Magnetic Luminex Assay Kit for Vascular Endothelial Growth Factor C (VEGFC) ,etc.
Magnetic Luminex Assay Kit for Vascular Endothelial Growth Factor C (VEGFC) ,etc.
Product No.
LMA145Ra
Organism Species
Rattus norvegicus (Rat).
Sample Type
Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Test Method
Double-antibody Sandwich
Assay Length
3.5h
Detection Range
0.98-1000pg/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 0.327 pg/mL.
UOM
1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex
Specificity
This assay has high sensitivity and excellent specificity for detection of Vascular Endothelial Growth Factor C (VEGFC) ,etc..
No significant cross-reactivity or interference between Vascular Endothelial Growth Factor C (VEGFC) ,etc. and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor C (VEGFC) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor C (VEGFC) ,etc. in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 91-98 | 94 |
| EDTA plasma(n=5) | 78-98 | 83 |
| heparin plasma(n=5) | 86-105 | 91 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor C (VEGFC) ,etc. were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor C (VEGFC) ,etc. were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor C (VEGFC) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 87-97% | 78-104% | 82-99% | 91-102% |
| EDTA plasma(n=5) | 80-89% | 98-105% | 84-102% | 84-102% |
| heparin plasma(n=5) | 94-101% | 91-103% | 98-105% | 93-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:VEGFC) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
| Magazine | Citations |
| Journal of Cellular Biochemistry | Alternatively activated RAW264. 7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma PubMed: 19241443 |
| genetics and molecular research | Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages PubMed: 26125824 |
| Experimental and Therapeutic | Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia PubMed: 26622498 |
| Am J Pathol | IL-10 Indirectly Regulates Corneal Lymphangiogenesis and Resolution of Inflammation via Macrophages PubMed: 26608451 |
| PLoS One. | Interleukin-6 Induces Vascular Endothelial Growth Factor-C Expression via Src-FAK-STAT3 Signaling in Lymphatic Endothelial Cells. pubmed:27383632 |
| Oncology Letters | RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth andinduces apoptosis in mouse breast cancer in vitro and in vivo. pubmed:27895746 |
| Angiogenesis | Characterization of isolated liver sinusoidal endothelial cells for liver bioengineering Pubmed:29582235 |
| Oncology Reports | Effects of diphyllin as a novel V-ATPase inhibitor on TE-1 and ECA-109 cells Pubmed:29328465 |
| LABORATORY INVESTIGATION | Dynamic signature of lymphangiogenesis during acute kidney injury and chronic kidney disease Pubmed: 31019289 |
| Cutaneous and Ocular Toxicology | Isotretinoin does not alter VEGF-A and VEGF-C levels: Do retinoids behave differently in dose-dependent and/or in vivo/in vitro conditions? Pubmed: 32722957 |
Share
